Human Xt-M (IL:HUMX.M)
TASE:HUMX.M
Want to see IL:HUMX.M full AI Analyst Report?
Top Page
Human Xt-M
(TASE:HUMX.M)
Select Model
Select Model
Rating:46Neutral
Price Target:
23.00
▼(-10.85% Downside)
Action:Upgraded
Date:01/28/26
The score is held down primarily by weak financial performance, including a major 2024 revenue decline, negative gross profit, large losses, and persistent cash burn despite low debt. Technicals offer only modest support via short-term strength, while valuation is constrained by a loss-making profile (negative P/E) and no dividend yield support.
Positive Factors
Very low leverage
Zero reported debt materially reduces refinancing and interest-rate risk and preserves financial optionality. Over a 2–6 month horizon this strengthens the firm's ability to negotiate restructuring, access capital markets if needed, and prioritize operational fixes without immediate debt-service pressure.
Negative Factors
Sharp 2024 revenue collapse and negative gross profit
A ~74% revenue drop paired with negative gross profit indicates unit economics are broken and costs exceed sales. Structurally, this undermines margin sustainability and means simple volume recovery alone won’t restore profitability; durable remediation requires major cost or business-model changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Zero reported debt materially reduces refinancing and interest-rate risk and preserves financial optionality. Over a 2–6 month horizon this strengthens the firm's ability to negotiate restructuring, access capital markets if needed, and prioritize operational fixes without immediate debt-service pressure.
Read all positive factors
Human Xt-M (HUMX.M) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪4.41M
Dividend YieldN/A
Average Volume (3M)50.09K
Price to Earnings (P/E)―
Beta (1Y)-0.18
Revenue Growth-100.00%
EPS Growth94.47%
CountryIL
Employees21
SectorTechnology
Sector Strength88
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding26,756,048
10 Day Avg. Volume22,744
30 Day Avg. Volume50,094
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Human Xt-M Business Overview & Revenue Model
Company Description
Human Xtensions Ltd. develops, manufactures, markets and sells a modular medical device for minimally invasive surgical operations. It offers HandX, a handheld electromechanical device for use in laparoscopic procedures; Fenestrated Grasper; Monop...
How the Company Makes Money
Human Xt (HUMX) generates revenue through the sale of its smart wearable devices and augmented reality applications, which are available to both individual consumers and corporate clients. The company also offers AI-driven software solutions on a ...
Human Xt-M Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
16
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Human Xt-M Technical Analysis
Negative
25.80
Price Trends
19.90
Negative
19.35
Negative
23.27
Negative
Market Momentum
-0.21
Negative
30.11
Neutral
65.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:HUMX.M, the sentiment is Negative. The current price of 25.8 is above the 20-day moving average (MA) of 18.46, above the 50-day MA of 19.90, and above the 200-day MA of 23.27, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 30.11 is Neutral, neither overbought nor oversold. The STOCH value of 65.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:HUMX.M.
Human Xt-M Peers Comparison
UnderperformOutperform
Sector (61)
IL:HUMX.M
Human Xt-M
16.50
-17.00
-50.75%
IL:BIOV
Bio View
14.10
-11.90
-45.77%
IL:ALMD
Allmed Solution
35.50
5.30
17.55%
IL:MPRS
Mediprss Pu
54.10
-7.70
-12.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.